Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi- bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be- tween efficacy and safety of a new drug. This goal often involves time and many different specialists.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
EUR 5,60 expédition vers Etats-Unis
Destinations, frais et délaisEUR 13,80 expédition depuis Royaume-Uni vers Etats-Unis
Destinations, frais et délaisVendeur : Nicholas J. Certo, Newburgh, NY, Etats-Unis
Hardcover. Etat : As New. A fresh as new copy in publishers glazed pictorial boards. N° de réf. du vendeur green 19-11 medical red/blak boards Ama
Quantité disponible : 1 disponible(s)
Vendeur : Schätze & Co., Münnerstadt, KG, Allemagne
Gr. 8°, Hardcover. Etat : Sehr gut. Ill., 251 S. Sprache: Englisch; sehr gutes Ex. Sprache: Englisch Gewicht in Gramm: 730. N° de réf. du vendeur 12190
Quantité disponible : 1 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783764358976_new
Quantité disponible : Plus de 20 disponibles
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists. This monograph contains a description of the discovery and development of a new antisecretory therapy in the treatment of acid-related diseases: omeprazole, the first proton pump inhibitors, the pharmaceutical delivery system and the clinical experience with proton pump inhibitors is reviewed. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9783764358976
Quantité disponible : 1 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists. 251 pp. Englisch. N° de réf. du vendeur 9783764358976
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. N° de réf. du vendeur 42529264
Quantité disponible : Plus de 20 disponibles
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9783764358976
Quantité disponible : Plus de 20 disponibles
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. This monograph contains a description of the discovery and development of a new antisecretory therapy in the treatment of acid-related diseases: omeprazole, the first pump inhibitor. The pharmacology of different proton pump inhibitors and the pharmaceutic delivery system are reviewed. Editor(s): Olbe, Lars. Series: Milestones in Drug Therapy. Num Pages: 261 pages, biography. BIC Classification: MJH; MMG. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 244 x 170 x 20. Weight in Grams: 730. . 1999. Hardback. . . . . N° de réf. du vendeur V9783764358976
Quantité disponible : 15 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. x + 251. N° de réf. du vendeur 2614419330
Quantité disponible : 4 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists. 268 pp. Englisch. N° de réf. du vendeur 9783764358976
Quantité disponible : 1 disponible(s)